COPENHAGEN, Oct 10 (Reuters) - Danish biotech firm Genmab on Thursday announced positive results from a phase IIstudy of its sclerosis drug candidate ofatumumab.
In a randomised study of 232 patients withrelapsing-remitting multiple sclerosis, treatment withofatumumab significantly reduced the cumulative number of newbrain lesions, the company said.
Relapsing-remitting multiple sclerosis is the most commonform of multiple sclerosis, which is an inflammatory disease ofthe central nervous system.
"We are encouraged by the results from this study," Genmab'schief executive Jan van de Winkel said in the statement.
There were no unexpected safety findings in the study,Genmab said.
Ofatumumab is being developed under a co-development andcommercialization agreement between Genmab and Britain'sGlaxoSmithKline Plc. Ofatumumab is sold under the nameArzerra for the treatment of blood cancer.
- Health Care Industry
- multiple sclerosis